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Introduction: Mitral regurgitation (MR) is the most common valvular disease and has recently
been the target of a number of percutaneous approaches. The MitraClip is virtually the only
device for which there is considerable experience, with more than 20 000 procedures performed
worldwide.
Objective: To describe our initial experience of the percutaneous treatment of MR with the
MitraClip device.
Methods: We describe the ﬁrst six MitraClip cases performed in this institution (mean age
58.5±13.1 years), with functional MR grade 4+ and New York Heart Association (NYHA) heart
failure class III or IV (n=3), with a mean follow-up of 290±145 days.
Results: Procedural success (MR ≤2+) was 100%. Total procedure time was 115.8±23.7 min, with
no in-hospital adverse events and discharge between the fourth and eighth day, and consistent
improvement in the six-minute walk test (329.8±98.42 vs. 385.33±106.95 m) and in NYHA class
(three patients improved by two NYHA classes). During follow-up there were two deaths, in two
of the four patients who had been initially considered for heart transplantation.
Conclusion: In patients with functional MR the MitraClip procedure is safe, with both a high
implantation and immediate in-hospital success rate. A longer follow-up suggests that the clini-
cal beneﬁt decreases or disappears completely in patients with more advanced heart disease,
namely those denied transplantation or on the heart transplant waiting list.
© 2014 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L.U. All rights
reserved. Please cite this article as: Cacela D, Fiarresga A, Branco L, et al. Terapêutica percutânea da insuﬁciência mitral: experiência inicial com
o dispositivo MitraClip. Rev Port Cardiol. 2015;34:515--524.
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Terapêutica percutânea da insuﬁciência mitral: experiência inicial com o dispositivo
MitraClip
Resumo
Introduc¸ão: A insuﬁciência valvular mitral (IM) é a valvulopatia mais comum e comec¸a agora a
ser alvo de abordagens percutâneas. O dispositivo MitraClip é virtualmente o único dispositivo
com uma experiência considerável, ultrapassando atualmente as 20 000 implantac¸ões.
Objetivo: Descrever a experiência inicial da terapêutica percutânea da IM com o dispositivo
MitraClip.
Métodos: Descrevem-se os primeiros seis casos de MitraClip realizados nesta instituic¸ão (idade
58,5± 13,1 anos), com IM 4+ de etiologia funcional e insuﬁciência cardíaca classe III ou IV (n = 3)
da New York Heart Association (NYHA), sem indicac¸ão cirúrgica ou recusados para cirurgia, com
um follow-up médio 290± 145 dias avaliado clinicamente pela sobrevivência, classe funcional,
teste da marcha dos seis minutos, estudo ecocardiográﬁco e determinac¸ão do proBNP.
Resultados: O sucesso do procedimento (IM ≤2 +) foi de 100%, com um tempo de procedi-
mento de 115,8± 23,7mins, sem intercorrências intra-hospitalares, alta entre o 4.◦ e 8.◦
dia e uma melhoria consistente no teste da marcha dos seis minutos (329,8± 98,42 versus
385,3± 106,95m) e da classe funcional (três dos pacientes com melhoria de duas classes fun-
cionais NYHA). Na totalidade do follow-up (290± 145 dias) constatam-se dois óbitos, em dois
dos quatro pacientes que tinham sido considerados para transplantac¸ão cardíaca.
Conclusões: O procedimento de implantac¸ão do dispositivo MitraClip é seguro, com uma alta
taxa de sucesso imediato nos pacientes com IM funcional. A médio prazo o benefício clí-
nico parece esbater-se ou anular-se nos pacientes com insuﬁciência cardíaca mais terminal,
nomeadamente nos pacientes a aguardar ou recusados para transplante.






































metry, whether due to ischemia or other processes, canntroduction
itral regurgitation (MR), of varying severity, is the most
ommon valvular disorder, with a prevalence of 1.7%, incre-
sing to 10% in those aged over 75.1 However, around half
f patients with severe MR are not referred for surgery,
ainly due to advanced age, comorbidities or severe left
entricular dysfunction.2 Of those who do undergo surgery,
nly 34--53%3 are treated by valvuloplasty rather than valve
eplacement.
There are two types of MR: anatomical, in which one of
he elements of the valve apparatus (annulus, leaﬂets or
hordae) is dysfunctional; and functional, in which there is
geometric and/or functional alteration in the left ven-
ricle that changes the normal relationship between these
lements.
Sooner or later, severe MI leads to left ventricular
ysfunction and hence congestive heart failure. Although
edical therapy can relieve symptoms, it does not alter
rogression of the disease, which is responsible for annual
ortality of ≥5% in symptomatic individuals.4,5 Another rea-
on for the large number of patients with severe MR who
re not referred for surgery is that its beneﬁt in functio-
al MR is unproven. Although functional MR is 5--10 times
ore prevalent than anatomical MR or aortic stenosis,6 sur-
ical treatment has only a class IIb recommendation in the
uropean and American guidelines for chronic secondary MR
nless coronary artery bypass grafting is also indicated.7
ercutaneous procedures thus do not in fact compete with
urgery for the treatment of functional MR.Treatment of MR was until recently exclusively surgical,
ut in recent years a number of percutaneous approaches
ave been developed, of which the most widely used with
onsistent results involves implantation of a clip device, the
itraClip (Abbott Laboratories, Abbott Park, IL, USA).
There have been various approaches for the treatment of
R:
Annulus: this D-shaped oriﬁce, which is in fact the left
atrioventricular junction,1 is nonplanar, with elevated
septal and lateral segments. The goal of surgical annu-
loplasty is to decrease the septal-to-lateral diameter by
at least 8 mm.8
Leaﬂets: the anterior leaﬂet is in ﬁbrous continuity with
the coronary and non-coronary leaﬂets of the aortic valve,
and has a wider surface with a shorter base, guarding only
one-third of the left atrioventricular junction, than the
posterior leaﬂet. The surface area of both leaﬂets taken
together is 2.5 times the area of the valvular oriﬁce. In
systole, the leaﬂets coapt over a height of, on average,
8 mm, giving a ‘‘coaptation reserve’’ in case of annular
dilation.1
Chordae tendineae: these connect the valve leaﬂets to
the ventricular free wall via the papillary muscles or
directly to the wall (basal cords).
Ventricular geometry: changes in left ventricular geo-severely disrupt the dynamics of mitral coaptation.9
Dyskinesia can alter the orientation of the basal cords,
leading to tethering of the posterior leaﬂet, and
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tFigure 1 Anatomical criteria for MitraClip implantation (besid
coaptation depth <11 mm; coaptation length >2 mm. Adapted
(Abbott Vascular).
ventricular dilatation can cause the papillary muscles
to move apically, leading to leaﬂet tenting and loss of
coaptation.
The Alﬁeri stitch is a surgical treatment for severe MR
due to incomplete leaﬂet coaptation that consists of sutu-
ring together the free edges of the middle segments of the
anterior and posterior leaﬂets (A2 and P2 scallops), together
with annuloplasty,10 and conﬁguring the valve with a double
oriﬁce. However, the group who developed this procedure
discovered that omitting the annuloplasty often produced
a good hemodynamic result, which was the rationale for a
percutaneous approach with the MitraClip.11
Methods
Of a total of 20 patients referred for this procedure
over a two-year period, six were initially selected for the
treatment after transthoracic and transesophageal echocar-
diographic assessment. Clinical criteria were functional MR
grade 4+, New York Heart Association (NYHA) class III or
IV and previous admissions for heart failure, and they also
had to have exhausted all other treatment options, surgical
or otherwise, including cardiac resynchronization therapy.
Most of those referred were being followed in heart fai-
lure clinics. Patients who fulﬁlled the clinical criteria also
had to meet the anatomical criteria (Figure 1) for implanta-
tion of the MitraClip device. As the technique has become
more widespread, the initially proposed anatomical criteria
have been somewhat modiﬁed, but they should be closely
followed by centers beginning to use the procedure. The
criteria are: central MR jet; coaptation length >2 mm and





Table 1 Demographic and clinical characteristics of the study po
Patient Gender Age (years) EF (%) EVER II LVESD
1 F 57 24 N 65
2 M 62 45 S 48
3 F 48 22 N 59
4 M 49 33 S 45
5 M 52 26 N 61
6 M 83 38 S 52
EF: ejection fraction; ES II: EuroSCORE II; EVER II: EVEREST II criteria; F
left ventricular end-diastolic diameter in mm; M: male; MR: mitral reg
Org: organic or degenerative MR; Y: yes.itral area of ≥4.0 cm2): ﬂail gap <10 mm; ﬂail width <15 mm;
permission from the Transesophageal Echo Acquisition Guide
ap and ﬂail width should be no more than 10 and 15 mm,
espectively.
These criteria inevitably exclude patients with severe
eft ventricular dilatation, since dilatation of the annulus
eparates the leaﬂets to such an extent that it is extremely
ifﬁcult to implant the clip. All echocardiographic records
ere reviewed by a proctor, who decided on the feasibility
f the procedure.
In demographic terms (Table 1) this initial experience
nvolved relatively young patients (mean age 58.5±13.1
ears), with a mean ejection fraction (EF) of 29±10.36% and
ogistic European System for Cardiac Operative Risk Evalu-
tion (EuroSCORE) of 20.06±16.86. Four patients had been
ssessed for heart transplantation, one of whom had been
ejected due to ﬁxed pulmonary vascular resistance. Three
atients would have been excluded from the Endovascular
alve Edge-to-Edge Repair Study (EVEREST II) trial12 due to
F <25% and/or left ventricular end-systolic dimension of
55 mm (mean 55.0±7.19 mm).
The selected patients underwent transthoracic echocar-
iography before the procedure, at discharge, and at one,
ix and 12 months, as well as clinical assessment, pro-
rain-type natriuretic peptide (proBNP) measurement, and
ix-minute walk test the day before implantation and at one,
ix and 12 months post-implantation. All patients gave their
ritten informed consent.
Procedural success was deﬁned as grade 2+ or less MR in
he absence of complications.12
The MitraClip resembles a clothes-peg, and is made of
obalt chromium, 4 mm wide, with two articulated arms
hat open from 0◦ (closed position) to 240◦ (open position),
nd uses a delivery system (Figures 2 and 3) that enables
he arms to be opened and closed and the device to be
pulation.
log ES ES II Func Org MR NYHA Etiology
12.04 3.24 Y N 4 IV Ischemic
10.73 1.64 Y N 4 III Myocarditis
12.04 4.50 Y N 4 IV Dilated
8.96 2.1 Y N 4 III Dilated
19.58 2.3 Y N 4 IV Dilated
57.03 9.5 Y N 4 III Ischemic
: female; Func: functional MR; log ES: logistic EuroSCORE; LVESD:
urgitation grade; N: no; NYHA: New York Heart Association class;








































aneuvered in three dimensions (rotated and moved in
nterior, posterior, lateral and medial directions).
The procedure is performed under general anesthesia.
ia a femoral approach, a 24F delivery system is intro-
uced into the left atrium following transseptal puncture,
nder ﬂuoroscopic and transesophageal echocardiographic
uidance. Three-dimensional echocardiography is essential,
ince it allows simultaneous visualization in two orthogo-
al planes (x-plane mode) and thus helps to ﬁne-tune the
elivery and placement of the device and ﬁxation of the lea-
ets. The clip is moved to the base of the regurgitant ﬂow
nd grasps the mid segments of both leaﬂets, bringing them
ogether, and is only released when the jet is deemed to be
ufﬁciently reduced (Figure 4). If the leaﬂets cannot be cor-
ectly ﬁxed, the arms can be opened to release the leaﬂets,
nd the clip withdrawn to the left atrium to be repositioned.
etween one and four clips are usually implanted. Following
mplantation, a ﬁbrous bridge forms between the two lea-
ets, providing additional strength and reducing the risk of
eptal-lateral distension.
The procedures were performed in the catheterization
























arta, Lisbon, under general anesthesia and two- and three-
imensional transesophageal echocardiographic guidance
Figure 5). Three proctors (an interventional cardiologist,
n echocardiographic cardiologist and a device technician)
ere present for the ﬁrst two cases and one, a device tech-
ician, was present for the others. Following transseptal
uncture and administration of intravenous heparin to achi-
ve an activated clotting time >250 s, the 22F MitraClip
elivery system was positioned in the left atrium via a 24F
heath in the right femoral vein. One MitraClip was placed
t the base of the regurgitant jet, dividing it into two; if
hese jets were small, the clip was implanted, otherwise
wo clips were used (Figure 6), implanting the ﬁrst in a mid
osition and the second more laterally (Figure 7), which was
nly released after conﬁrmation that there was no signi-
cant transmitral gradient. If the leaﬂets were particularly
ifﬁcult to grasp, a brief period of apnea was induced by dis-
onnecting the patient from the ventilator for a few seconds
nd/or intense bradycardia was induced by administering a
hort half-life beta-blocker (esmolol).
In accordance with our protocol, patients were extubated
n the catheterization laboratory and transferred already
onscious to the intensive care unit (ICU) for 24 hours, after
hich they were transferred to the ward.
Since ﬁve patients were under oral anticoagulation with
cenocoumarol or warfarin, clopidogrel was prescribed for
month following the procedure only in the remaining pati-
nt, who was taking aspirin.
Results of the statistical analysis of quantitative varia-
les in these six cases were expressed as means ± standard
eviation.
esults
rocedural success in these six patients was 100%, with no
dverse events during the intervention or during hospital
tay (mean 6.2±1.48 days).
Although the intervention is relatively lengthy
115.8±23.7 min), ﬂuoroscopy time is relatively short







these, one had been rejected due to ﬁxed pulmonary vas-
cular resistance and the other was in terminal heart failureFigure 4 (A) Positioning of the MitraClip in the center of the
clip inserted and released. Adapted by permission from Abbott
(49.2±19.38 min), because the procedure is mainly guided
by transesophageal echocardiography (Table 2).
Echocardiographic assessment (Tables 3 and 4) revealed
improvement in left ventricular end-diastolic (229.5±118.53
vs. 182.5±88.24 ml) and end-systolic (158.2±100.28 vs.
127.2±57.71 ml) volume, EF (31.3±8.2 vs. 37.3±6.11%)
and pulmonary artery systolic pressure (44.5±16.75 vs.
41.0±9.97 mmHg).
At one-month follow-up (Table 5), functional status had
improved in ﬁve of the six patients, with an improvement
Figure 5 Three-dimensional echocardiographic image of the




Mrgitant jet; (B) view of the MitraClip from the atrial side; (C)
ular.
f one (two patients) or two (three patients) NYHA clas-
es. There were a total of three readmissions (two in one
atient) and two deaths, in two of the four patients who
ad been initially considered for heart transplantation. Ofefore the MitraClip procedure. This patient was readmit-
ed a month later for congestive heart failure and died 84
igure 6 Angiographic image of the release of a second
itraClip.
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Figure 7 Implantation of a second MitraClip. If it is expected that a second clip will be required, the ﬁrst should be placed in a
mid position and the second more laterally. (A and B) Conﬁrmation in different views of the position of the MitraClip; (C) the two
mitral valve leaﬂets are grasped by the MitraClip; (D) after release, with residual regurgitation jets.
Table 2 Procedural data and hospital stay.
Patient 1 2 3 4 5 6 Mean ± SD
Fluoroscopy time (min) 41 73 35 26 78 42 49.2± 19.38
Procedure time (min) 80 155 110 105 135 110 115.8± 23.7
Device time (min) 60 130 85 85 100 90 91.7± 20.9
Radiation dose (mGy) 915 2680 1487 209 4456 2026 1962.2± 1362.3
No. of clips implanted 1 2 1 1 2 1 1.3± 0.47
Hospital stay after procedure (days) 6 6 7 4 8 5 6.0± 1.29
Device time: time between entry of the steerable guide catheter into the left atrium via the interatrial septum and withdrawal of the
MitraClip delivery catheter into the steerable guide catheter; Procedure time: time between transseptal puncture and removal of the
steerable guide catheter.
Table 3 Echocardiographic evolution of mitral regurgitation and ventricular volumes.
Pt MRb MR1 MR6 MR12 LVEDVb LVEDV1 LVEDV6 LVEDV12 LVESVb LVESV1 LVESV6 LVESV12
1 4 1 2 1--2 443 390 403 337 360 315 312 228
2 4 1 2 2 110 119 99 95 60 66 51 71
3 4 3 2--3 d 134 151 139 d 105 101 107 d
4 4 2 1 -- 142 136 102 -- 96 101 76 --
5 4 3 4a d 317 262 d -- 204 181 d --
6 4 1 -- -- 231 160 -- -- 124 100 -- --
b, 1, 6, 12: baseline, 1 month, 6 months, 12 months, respectively; d: died; LVEDV: left ventricular end-diastolic volume in ml; LVESV:
left ventricular end-systolic volume in ml; MR: mitral regurgitation grade; Pt: patient.a Last echocardiographic assessment before death.
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Table 4 Echocardiographic evolution of ejection fraction and pulmonary artery systolic pressure.
Patient EFb EF1 EF6 EF12 PASPb PASP1 PASP6 PASP12
1 24 17 23 33 33 33 38 33
2 45 44 44 25 24 35 32 42
3 22 33 23 d 78 58 62 d
4 33 26 25 -- 42 57 36 --
5 26 19 d -- 44 33 d --
6 38 37 -- -- 46 40 -- --









































days after admission without a donor having been found;
he was the only patient in whom proBNP had risen signi-
ﬁcantly at one-month follow-up, all the others showing a
fall in this parameter (557.8±376.73 vs. 494.2±249.5 ng/l).
The patient who had been denied transplantation was brieﬂy
admitted twice within six months of MitraClip implantation
(before the procedure she had been admitted virtually every
month) and suffered outpatient sudden death after nine
months.
The one-month six-minute walk test showed an impro-
vement in all patients (329.8±98.42 vs. 385.33±109.95 m).
The four patients still alive at the end of follow-up (290±140
days) maintained an improvement of one or two NYHA func-
tional classes (Table 5).
Discussion
The six cases described constitute our initial experience with
the MitraClip. This small number, together with a still short
follow-up and the fact that the echocardiographic studies
were not evaluated by an independent laboratory, are the
main limitations of this study and prevent any generalizati-
ons. Nevertheless, the most striking ﬁnding is the safety of
the intervention.
We began using this procedure after a two-year period
of patient selection, which included detailed study of the
mitral anatomy by transthoracic and transesophageal echo-
cardiography. There are currently eight patients on the
waiting list, all with severe MR and symptoms of heart fai-
lure. Accumulated experience worldwide suggests that when
a center ﬁrst begins to use the device only one in three
patients referred for MitraClip implantation is considered
suitable.
The device received CE Mark approval in 2008 and US
Food and Drug Administration approval in 2013, the latter
on the basis of the EVEREST II trial, in which 279 patients
with MR grade 3+ or 4+ were randomized in a 2:1 ratio to
MitraClip or surgery (repair or replacement). The primary
composite endpoint for efﬁcacy was freedom from death,
from surgery for mitral valve dysfunction, and from grade
3+ or 4+ MR at 12 months, and the primary safety endpoint
was a composite of major adverse events within 30 days.
The rates of the primary end point for efﬁcacy were 55% in
the MitraClip group and 73% in the surgery group (p=0.007),
with 6% mortality in each group, 20% vs. 2% surgery for mitral
valve dysfunction, and 21% vs. 20% grade 3+ or 4+ MR. The
rates for the safety endpoint were 15% vs. 48% (p<0.001). At
t
m
t2 months, both groups had improved left ventricular size,
YHA functional class, and quality-of-life measures.
Of the patients treated with the MitraClip, 41 (23%)
ad grade 3+ or 4+ MR before hospital discharge and were
eferred for surgery. Of these 41 patients, 28 underwent sub-
equent mitral valve surgery. In the surgery group, mitral
alve replacement was performed in 14% and repair in 86%.
Transfusion of ≥2 units of blood (which has an important
ffect on late outcomes13) comprised the largest single com-
onent of major adverse events at 30 days. Even after the
xclusion of transfusion events, the rate of adverse events
as lower in the MitraClip group.
In two subgroups in the MitraClip arm, those with functio-
al MR and patients aged ≥70 years, efﬁcacy was not inferior
o surgery. Four-year results in the EVEREST II trial show
3% survival in the MitraClip group and 82% in the surgical
roup, and no signiﬁcant difference in the number of pati-
nts with MR grade 3+ or 4+.14 The efﬁcacy and safety of the
evice compared with medical therapy in high-risk patients
as been conﬁrmed by the European ACCESS-EU registry15
nd the German TRAnscatheter Mitral valve Interventions
TRAMI) registry.16 Also comparing the MitraClip with stan-
ard of care are the randomized trials Clinical Outcomes
ssessment of the MitraClip Percutaneous Therapy for Extre-
ely High Surgical Risk Patients (COAPT) in the USA and A
andomized Study of the MitraClip Device in Heart Failure
atients with Clinically Signiﬁcant Functional Mitral Regur-
itation (RESHAPE-HF) in Europe.
The most striking demographic feature in our series was
he relatively young age of the patients (only one octoge-
arian; mean age 58.5±13.1 years), which was the main
eason for the low logistic EuroSCORE of 20.06±16.86. Given
he weight attributed to age in this risk score, the real risk
f these patients may have been underestimated, as indi-
ated by the two non-procedure-related deaths in the 12
onths after implantation. The purpose of selecting such
oung patients was to use the device in those with the lon-
est expected survival, who would thus obtain the maximum
ossible beneﬁt from the procedure. The idea of choosing
atients who were under consideration for heart transplan-
ation was to postpone for as long as possible -- ideally for
ears -- the need to go on the waiting list for a donor. Howe-
er, the results suggest that in some of these patients, the
atural history of the disease has progressed too far for
hem to derive any beneﬁt. Patient selection remains the
ost important factor, since the purpose of the MitraClip is
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quarter of patients experience little or no symptomatic
elief.
Other series of patients mainly with functional MR,17
ncluding the largest European registry and the one that is
erhaps closest to our experience, ACCESS-EU,15 show that
2--83% of patients who survive to one-year follow-up have
rade ≤2+ MR and 79--83% are in NYHA class I or II. Hospi-
al stay in ACCESS-EU was slightly longer than in our series
7.7±8.2 days, including 2.5±6.5 days in the ICU), and as in
ur series there was consistent improvement in echocardi-
graphic parameters and in the six-minute walk test; in the
atter the mean gain was around 60 m, also similar to our
xperience (55 m). Hospital stay in European series tends to
e longer than in US registries, in which the average is three
ays.
Historically, US and European approaches have differed.
VEREST I18 and II were American trials, and they gave ini-
ial credibility to the MitraClip device; their patients also
ad to be candidates for surgery. In Europe, by contrast,
he focus has been more on patients who would be ineli-
ible for such trials: those with severe functional MR and
eart failure, not considered suitable for surgery and often
on-responders to cardiac resynchronization therapy, most
f whom are being followed in heart failure clinics and
ome under consideration for or denied transplantation, as
ere four of our patients. In Europe MitraClip implanta-
ion is perceived as a procedure that does not compete
ith surgery for patients who have no non-pharmacological
lternative. Thus, unlike in EVEREST II, in which 73% of the
rial population had degenerative MR, in our series all six
atients had functional MR. As a result, unlike transcathe-
er aortic valve replacement, there is little possibility of
turf war between interventional cardiology and cardiac
urgery.
There are two patient groups for whom MitraClip the-
apy is particularly attractive: those with severe annular
alciﬁcation, since this can act as a prosthetic ring to pro-
ide additional support and thus prevent progressive annular
ilatation; and those with severe functional MR and heart
ailure refractory to pharmacological and resynchronization
herapy (non-responders).19
Despite the successful and increasing use of the proce-
ure, the MitraClip does have some potential limitations.20
t is not a complete substitute for the Alﬁeri stitch, since
t does not treat the annulus, which may explain the recur-
ence of signiﬁcant MR in the medium to long term; it can
e difﬁcult to quantify MR, particularly residual regurgita-
ion after implantation of the clip during a procedure under
eneral anesthesia (although this problem is also found with
urgery); MR could be replaced by mitral stenosis, although
o cases have been reported to date21; and there are no data
n its long-term durability and efﬁcacy.
Meanwhile, as the procedure has become more wides-
read, the initial anatomical criteria have been widened,
ith cases reported of treatment of eccentric MR, and vari-
tions on the original technique have been developed, such
s the zipping technique, in which four or ﬁve clips are
mplanted.
There are a growing number of percutaneous MR the-
apies besides the MitraClip, some of them already being













1Percutaneous treatment of mitral valve regurgitation
according to whether they involve the annulus or other ele-
ments of the mitral valve apparatus.
In most surgical approaches to MR, the two main compo-
nents of the valve, the leaﬂets and the annulus, are treated.
It is thus understandable that there has also been extensive
research into percutaneous interventions on the annulus,
which in fact precedes the development of the MitraClip.
There are two forms of percutaneous annuloplasty, indi-
rect and direct. The CARILLON Mitral Contour System
(Cardiac Dimensions) is an indirect annuloplasty device con-
sisting of two nitinol anchors connected by a central nitinol
element, positioned in the coronary sinus. It is delivered via
a 9F catheter through the internal jugular vein, and ten-
sion on the device is adjusted manually by moving it 4--5 cm
before ﬁnal release. The procedure is monitored by tran-
sesophageal echocardiography, to assess MR grade, and left
coronary angiography, to exclude coronary compression. It is
the only percutaneous annuloplasty device currently appro-
ved in the European Union.
Unlike indirect annuloplasty devices, which are positi-
oned in the coronary sinus, direct approaches treat the
annulus itself, as in surgical repair. Access is more com-
plex with direct devices. With the Mitralign Bident system,
the device is introduced retrogradely via the femoral artery
and positioned in the left ventricle under the posterior lea-
ﬂet. Two pledget pairs are implanted in the annulus and
plicated with a Mitralign lock; the resulting tension brings
the leaﬂets closer together, reducing the annular circum-
ference. Another direct annuloplasty device is the Valtech
Cardioband, in which access is transseptal; this has been
used exclusively to treat functional MR.
Since patients treated by the MitraClip may suffer recur-
rence of their original grade of MR in the medium to long
term, the idea of associating annuloplasty is an attractive
one, since it more closely reproduces surgical repair, and
appears to be the most promising approach22 while we await
the development of a prosthetic mitral valve that can be
implanted percutaneously in the native valve.
Conclusions
Our initial experience with the MitraClip device conﬁrmed
the safety of the procedure in a group of patients with heart
failure and grade 4+ functional MR who were not considered
suitable for surgery, three of whom would have been exclu-
ded from the EVEREST II trial and four of whom had been
considered for heart transplantation.
The short follow-up does not allow a proper analysis of
the device’s efﬁcacy, but the absence of reintervention (sur-
gical or otherwise), improvements in functional class, left
ventricular volumes and six-minute walk test, and consistent
falls in proBNP levels, all suggest that it is at least reaso-
nable. However, MitraClip implantation does not appear to
alter the natural history of the disease in patients under
consideration for heart transplantation.
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